Literature DB >> 24599935

Beyond histology: translating tumor genotypes into clinically effective targeted therapies.

Catherine B Meador1, Christine M Micheel, Mia A Levy, Christine M Lovly, Leora Horn, Jeremy L Warner, Douglas B Johnson, Zhongming Zhao, Ingrid A Anderson, Jeffrey A Sosman, Cindy L Vnencak-Jones, Kimberly B Dahlman, William Pao.   

Abstract

Increased understanding of intertumoral heterogeneity at the genomic level has led to significant advancements in the treatment of solid tumors. Functional genomic alterations conferring sensitivity to targeted therapies can take many forms, and appropriate methods and tools are needed to detect these alterations. This review provides an update on genetic variability among solid tumors of similar histologic classification, using non-small cell lung cancer and melanoma as examples. We also discuss relevant technological platforms for discovery and diagnosis of clinically actionable variants and highlight the implications of specific genomic alterations for response to targeted therapy. ©2014 AACR.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24599935      PMCID： PMC4008689          DOI： 10.1158/1078-0432.CCR-13-1591

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  102 in total

1.  DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA.

Authors:  D Stehelin; H E Varmus; J M Bishop; P K Vogt
Journal:  Nature       Date:  1976-03-11       Impact factor: 49.962

2.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

Authors:  Keith T Flaherty; Jeffery R Infante; Adil Daud; Rene Gonzalez; Richard F Kefford; Jeffrey Sosman; Omid Hamid; Lynn Schuchter; Jonathan Cebon; Nageatte Ibrahim; Ragini Kudchadkar; Howard A Burris; Gerald Falchook; Alain Algazi; Karl Lewis; Georgina V Long; Igor Puzanov; Peter Lebowitz; Ajay Singh; Shonda Little; Peng Sun; Alicia Allred; Daniele Ouellet; Kevin B Kim; Kiran Patel; Jeffrey Weber
Journal:  N Engl J Med       Date:  2012-09-29       Impact factor: 91.245

3.  Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.

Authors:  Suresh S Ramalingam; Fiona Blackhall; Maciej Krzakowski; Carlos H Barrios; Keunchil Park; Isabel Bover; Dae Seog Heo; Rafael Rosell; Denis C Talbot; Richard Frank; Stephen P Letrent; Ana Ruiz-Garcia; Ian Taylor; Jane Q Liang; Alicyn K Campbell; Joseph O'Connell; Michael Boyer
Journal:  J Clin Oncol       Date:  2012-07-02       Impact factor: 44.544

4.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

Authors:  William Pao; Vincent Miller; Maureen Zakowski; Jennifer Doherty; Katerina Politi; Inderpal Sarkaria; Bhuvanesh Singh; Robert Heelan; Valerie Rusch; Lucinda Fulton; Elaine Mardis; Doris Kupfer; Richard Wilson; Mark Kris; Harold Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-25       Impact factor: 11.205

5.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

6.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

7.  Determinants of BRAF mutations in primary melanomas.

Authors:  Janet L Maldonado; Jane Fridlyand; Hetal Patel; Ajay N Jain; Klaus Busam; Toshiro Kageshita; Tomomichi Ono; Donna G Albertson; Dan Pinkel; Boris C Bastian
Journal:  J Natl Cancer Inst       Date:  2003-12-17       Impact factor: 13.506

8.  Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma.

Authors:  Lawrence N Kwong; James C Costello; Huiyun Liu; Shan Jiang; Timothy L Helms; Aliete E Langsdorf; David Jakubosky; Giannicola Genovese; Florian L Muller; Joseph H Jeong; Ryan P Bender; Gerald C Chu; Keith T Flaherty; Jennifer A Wargo; James J Collins; Lynda Chin
Journal:  Nat Med       Date:  2012-09-16       Impact factor: 53.440

9.  Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.

Authors:  William Pao; Vincent A Miller; Katerina A Politi; Gregory J Riely; Romel Somwar; Maureen F Zakowski; Mark G Kris; Harold Varmus
Journal:  PLoS Med       Date:  2005-02-22       Impact factor: 11.069

10.  Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma.

Authors:  Giovanni Ponti; Aldo Tomasi; Giovanni Pellacani
Journal:  J Hematol Oncol       Date:  2012-10-02       Impact factor: 17.388
View more
  25 in total

1.  Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service.

Authors:  Angela Hamblin; Sarah Wordsworth; Jilles M Fermont; Suzanne Page; Kulvinder Kaur; Carme Camps; Pamela Kaisaki; Avinash Gupta; Denis Talbot; Mark Middleton; Shirley Henderson; Anthony Cutts; Dimitrios V Vavoulis; Nick Housby; Ian Tomlinson; Jenny C Taylor; Anna Schuh
Journal:  PLoS Med       Date:  2017-02-14       Impact factor: 11.069

Review 2.  New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA.

Authors:  Elena Duréndez-Sáez; Aitor Azkárate; Marina Meri; Silvia Calabuig-Fariñas; Cristóbal Aguilar-Gallardo; Ana Blasco; Eloisa Jantus-Lewintre; Carlos Camps
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

Review 3.  Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Authors:  E Felip; Á Concha; J de Castro; J Gómez-Román; P Garrido; J Ramírez; D Isla; J Sanz; L Paz-Ares; F López-Ríos
Journal:  Clin Transl Oncol       Date:  2014-10-29       Impact factor: 3.405

Review 4.  Advances of small molecule targeting of kinases.

Authors:  Norbert Berndt; Rezaul M Karim; Ernst Schönbrunn
Journal:  Curr Opin Chem Biol       Date:  2017-07-18       Impact factor: 8.822

5.  ESCAT: a step in the right direction.

Authors:  A J Silver; J L Warner
Journal:  Ann Oncol       Date:  2018-11-01       Impact factor: 32.976

Review 6.  Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology.

Authors:  Kristoffer S Rohrberg; Ulrik Lassen
Journal:  Drugs       Date:  2021-01-05       Impact factor: 9.546

Review 7.  The evidence framework for precision cancer medicine.

Authors:  Jeffrey A Moscow; Tito Fojo; Richard L Schilsky
Journal:  Nat Rev Clin Oncol       Date:  2017-12-19       Impact factor: 66.675

8.  Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel.

Authors:  Douglas B Johnson; Kimberly H Dahlman; Jared Knol; Jill Gilbert; Igor Puzanov; Julie Means-Powell; Justin M Balko; Christine M Lovly; Barbara A Murphy; Laura W Goff; Vandana G Abramson; Marta A Crispens; Ingrid A Mayer; Jordan D Berlin; Leora Horn; Vicki L Keedy; Nishitha M Reddy; Carlos L Arteaga; Jeffrey A Sosman; William Pao
Journal:  Oncologist       Date:  2014-05-05

9.  Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.

Authors:  H Kotani; H Ebi; H Kitai; S Nanjo; K Kita; T G Huynh; A Ooi; A C Faber; M Mino-Kenudson; S Yano
Journal:  Oncogene       Date:  2015-11-09       Impact factor: 9.867

Review 10.  Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era: Current and Future Molecular-Based Testing.

Authors:  Kevin Shee; Kristen E Muller; Jonathan Marotti; Todd W Miller; Wendy A Wells; Gregory J Tsongalis
Journal:  Am J Pathol       Date:  2018-10-29       Impact factor: 4.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.